Status:

COMPLETED

Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours

Lead Sponsor:

Walter and Eliza Hall Institute of Medical Research

Collaborating Sponsors:

Royal Marsden NHS Foundation Trust

Melbourne Health

Conditions:

Testicular Neoplasms

Eligibility:

MALE

Brief Summary

Recent data (Srikanthan and Tran et al. JCO 2014, in press) have demonstrated that the presence of large retroperitoneal lymph node metastases on baseline staging scans (measuring \>5cm in axial dimen...

Detailed Description

Recent data (Srikanthan and Tran et al. JCO 2014, in press) have demonstrated that the presence of large retroperitoneal lymph node (RPLN) metastases on baseline staging scans (measuring \>5cm in axia...

Eligibility Criteria

Inclusion

  • Men with disseminated GCT (AJCC Stage IS, 2, or 3)
  • Received first line chemotherapy with curative intent for disseminated GCT
  • Clinical data available from chemotherapy initiation to at least 90 days following completion of chemotherapy (patients who died prior to 90 days will be included in this study)
  • Initiated chemotherapy between 1-January-2000 and 31-December-2014\* \*Data collection from consecutive patients initiating chemotherapy during a defined period within the specified timeframe is acceptable (e.g. patient data from 5-year period starting 1-January-2008 and ending 31-December-2012 is acceptable)

Exclusion

  • Prior chemotherapy for GCT (including use of adjuvant chemotherapy or curative chemotherapy for prior diagnosis of disseminated GCT).
  • History of secondary malignancy (excluding non-melanoma superficial skin cancers)

Key Trial Info

Start Date :

December 1 2015

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 16 2020

Estimated Enrollment :

1135 Patients enrolled

Trial Details

Trial ID

NCT04122430

Start Date

December 1 2015

End Date

October 16 2020

Last Update

October 19 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Walter and Eliza Hall Institute of Medical Research

Parkville, Victoria, Australia, 3052